ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Unipharma Co's annualizedNet Income for the quarter that ended in Dec. 2025 was NT$-33.47 Mil.
Unipharma Co's average Total Assets over the quarter that ended in Dec. 2025 was NT$283.30 Mil. Therefore, Unipharma Co's annualized ROA % for the quarter that ended in Dec. 2025 was -11.81%.
The historical rank and industry rank for Unipharma Co's ROA % or its related term are showing as below:
ROCO:6621'
s ROA % Range Over the Past 10 Years
Min: -19.48 Med: -6.85 Max: 4.64
Current: -13.58
During the past 13 years, Unipharma Co's highest ROA % was 4.64%. The lowest was -19.48%. And the median was -6.85%.
ROCO:6621's ROA % is ranked worse than 81.69% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 2.74
vs ROCO:6621: -13.58
Unipharma Co (ROCO:6621) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Unipharma Co ROA % Related Terms
Unipharma Co ROA % Historical Data
* Premium members only.
The historical data trend for Unipharma Co's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Unipharma Co's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Unipharma Co ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Unipharma Co's ROA % distribution charts can be found below:
* The bar in red indicates where Unipharma Co's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Unipharma Co (ROCO:6621) has a ROA % of -11.81% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Unipharma Co and its competitors. According to the industry distribution chart, Unipharma Co ranks #821 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 81.7%.
Is Unipharma Co's ROA % too high?
Unipharma Co's current ROA % is -11.81%. Based on the distribution chart, Unipharma Co ranks #821 out of 1005 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Unipharma Co has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Unipharma Co's ROA % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Unipharma Co ranks #821 out of 1005 companies for ROA %. This places Unipharma Co in the lower half of its industry. The industry median ROA % is 2.74. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.74, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Unipharma Co and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Unipharma Co's current ROA % is -11.81%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Unipharma Co stock overvalued right now?
Based on GuruFocus' analysis, Unipharma Co (ROCO:6621) is currently considered Fairly Valued. The stock's GF Value™ is NT$11.63, compared to a current price of NT$11.35 — trading 2.4% below its estimated fair value. The current ROA % is -11.81%. Unipharma Co's overall GF Score™ is 74/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Unipharma Co (ROCO:6621), the current ROA % is -11.81% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Unipharma Co (ROCO:6621) Overvalued in 2026?
Based on GuruFocus' analysis, Unipharma Co stock appears to be undervalued.
The current stock price of NT$11.35 is trading 2.4% below its estimated GF Value™ of NT$11.63.
GuruFocus considers Unipharma Co to be Fairly Valued.
Key valuation signals for ROCO:6621:
ROA %: -11.81%
GF Value™: NT$11.63 vs. price of NT$11.35 (2.4% below fair value)
No single metric tells the full story. See the ROCO:6621 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Unipharma Co Ltd is a medical diagnostic, pharmaceutical and medical device company. It is engaged in developing drug products and medical equipment. The company's products offerings include Baxter, Tambocor tablets, Bain Injection, Esmolol HCL Injection, Naloxone Injection, and SAM Pelvic Sling medical device. Its customers are major medical centers, regional hospitals, regional hospitals, and clinics.
74GF Score
Get the complete analysis for ROCO:6621
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6621 has been successfully added to your 
